Accelerated 15 mW pulsed-light crosslinking to treat progressive keratoconus: Two-year clinical results

J Cataract Refract Surg. 2017 Aug;43(8):1081-1088. doi: 10.1016/j.jcrs.2017.05.030.

Abstract

Purpose: To assess the clinical and microstructural results of accelerated 15 mW pulsed-light corneal crosslinking (CXL) to treat progressive keratoconus.

Setting: Siena Crosslinking Center, Siena, Italy.

Design: Prospective case series.

Methods: After epithelium removal (with Epi-Clear) and 10 minutes stromal soaking with riboflavin 0.1% hydroxypropyl methylcellulose solution, all eyes had 15 mW/cm2 pulsed-light epithelium-off accelerated CXL for 6 minutes of ultraviolet-A (UVA) irradiation (1 second on/1 second off), maintaining a total UVA exposure of 12 minutes at a fluence of 5.4 J/cm2. The 2-year follow-up examination included uncorrected (UDVA) and corrected (CDVA) distance visual acuities, Scheimpflug tomography, in vivo confocal microscopy (IVCM), and spectral-domain optical coherence tomography (SD-OCT).

Results: The study comprised 132 eyes of 96 patients (mean age 23.7 years ± 4.3 [SD]) with stage II keratoconus. The change in UDVA and CDVA was statistically significant, from 0.51 ± 0.106 logarithm of the minimum angle of resolution (logMAR) at baseline to 0.309 ± 0.074 logMAR (P = .0001) and 0.271 ± 0.144 logMAR at baseline to 0.135 ± 0.100 logMAR (P = .0023), respectively. Coma values measured by Scheimpflug analysis showed a statistically significant improvement beginning with the first postoperative month (P = .0004). The IVCM scans documented basal epithelial healing occurring 72 hours after treatment associated with the presence of subepithelial nerves. The SD-OCT scans performed in the central 6.0 mm of corneal diameter documented a demarcation line at a mean depth of 280 ± 32 μm.

Conclusion: The 15 mW/cm2 pulsed-light epithelium-off accelerated CXL was effective and safe, stabilizing keratoconus progression through 2 years of follow-up.

MeSH terms

  • Cross-Linking Reagents* / therapeutic use
  • Humans
  • Hypromellose Derivatives / therapeutic use*
  • Keratoconus* / drug therapy
  • Microscopy, Confocal
  • Prospective Studies
  • Riboflavin* / therapeutic use
  • Visual Acuity

Substances

  • Cross-Linking Reagents
  • Hypromellose Derivatives
  • Riboflavin